CAJ | 학술논문

目的探讨干扰素与阿德褊韦酯序贯治疗慢性乙型肝炎的临床疗效.方法将90例慢性乙型肝炎病人随机分成3组;干扰素组30例:单纯应用干扰素治疗,疗程至少1年;干扰素与阿德福韦酯组30例:先用干扰素治疗,疗程至少1年,再用阿德福韦酯治疗,疗程2年;阿德福韦酯组30例:单纯应用阿德福韦酯治疗,疗程3年.3组停药后均随访6个月,观察3组患者用药前、后的主要症状及体征变化,并检测用药前、后及随访6个月的血常规、肝功能、乙肝病毒标志物(HBeAg、HBeAb、HBV-DNA)等的变化.结果干扰素组显效13例、有效7例、无效10例;干扰素与阿德福韦酯组显效19例、有效6例、无效5例;阿德福韦酯组显效14例、有效5例、无效11例;3组总有效率方面比较,差异有极显著性(P＜0.01).讨论干扰素与阿德福韦酯的序贯治疗可持续抑制乙肝病毒,达到减轻或防止肝细胞损伤和疾病进展,从而改善患者的生活质量和延长存活时间.
목적 탐토간우소여아덕편위지서관치료만성을형간염적림상료효.방법 장90례만성을형간염병인수궤분성3조;간우소조30례:단순응용간우소치료,료정지소1년;간우소여아덕복위지조30례:선용간우소치료,료정지소1년,재용아덕복위지치료,료정2년;아덕복위지조30례:단순응용아덕복위지치료,료정3년.3조정약후균수방6개월,관찰3조환자용약전、후적주요증상급체정변화,병검측용약전、후급수방6개월적혈상규、간공능、을간병독표지물(HBeAg、HBeAb、HBV-DNA)등적변화.결과 간우소조현효13례、유효7례、무효10례;간우소여아덕복위지조현효19례、유효6례、무효5례;아덕복위지조현효14례、유효5례、무효11례;3조총유효솔방면비교,차이유겁현저성(P＜0.01).토론간우소여아덕복위지적서관치료가지속억제을간병독,체도감경혹방지간세포손상화질병진전,종이개선환자적생활질량화연장존활시간.
Objective To study the curative effects of sequential treatment by interferon and Adefovir Dipivoxil to chronic hepatitis b clinical. Methods 90 cases of chronic hepatitis b patients were randomly divided into 3 groups, interferon group of 30 cases: simple application interferon treatment, period of treatment for at least a year, interferon and Adefovir Dipivoxil group of 30 cases: first use interferon treatment for at least a year, reoccupy Adefovir Dipivoxil with a course of 2 years; Adefovir Dipivoxil group of 30 cases: simple application Adefovir Dipivoxil treatment, treatment for 3 years. 3 groups after discontinuation were conducted with all 6 months of follow-up, to observe the main symptoms and medication signs changes before and after therapy, liver function and hepatitis b virus (HBeAb, HBeAg, markers, HBV-DNA) as well as change. Results 13 excellent cases of interferon. 7 effective cases, invalid 10 cases, interferon and Adefovir Dipivoxil group 19 excellent cases, effective in 6 cases, invalid in 5 cases, Adefovir dipivoxil group got 14 cases, effective in 5 cases, invalid 11 cases. There were significant differences among these 3 groups in total effectiveness aspects (P＜ 0.01). Conclusion Sequential treatment of interferon and Adefovir Dipivoxil can restrain the hepatitis b virus and ease or prevent hepatocyte injury and disease progression, so as to improve the patients' life quality and prolong survival time.